UNH Research Update — July 17, 2026
Updated Thesis
UnitedHealth Group Incorporated operates in the healthcare sector, specifically within medical and healthcare plans, providing a durable business model supported by a strong competitive moat and consistent earnings growth. The company currently trades at a price of $423.38 with a market cap of $359.873 billion, reflecting a valuation that is cheap relative to its five-year history, supported by a P/E forward of 27.23 and an EV/EBITDA of 13.85. Despite modest revenue growth of 0.4% in the most recent quarter, earnings growth surged 61.0% in the same period, indicating strong operational leverage and profitability improvements.
The investment grade as of this refresh is B — solid business quality. High-tier business, cheap valuation with 45% upside to $613.90 fair value
Key Metrics at a Glance
- Revenue growth: +0.4% year over year
- Net margin: 2.7%
- Forward P/E: 27.2x
- Fair value upside: +45.0% to our estimate of $614
Current price: $423.38
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. UnitedHealth Group Incorporated remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full UNH research →](/stocks/UNH)